MI HB4472

Allows pharmacists to dispense interchangeable biological drug products as alternatives to brand name drugs, with the same restrictions and notification requirements as generic drug substitutions.

Requires pharmacists to notify prescribers within 5 days of dispensing an interchangeable biological drug product by electronic medical records, e-prescribing, pharmacy benefit management system, health information exchange, or pharmacy record.

Mandates that pharmacists pass cost savings to patients or third-party payment sources when dispensing lower-cost interchangeable biological drug products, calculated as the difference in wholesale cost between products.

Permits prescribers to prevent substitution by writing "dispense as written" or "d.a.w." on written prescriptions or initialing d.a.w. on preprinted prescription blanks.

Requires the state department to annually report to the legislature on biological drug products transitioning from the FDA's Orange Book (therapeutic equivalence) to the Purple Book (interchangeability evaluations) and projected completion date.